HOUSTON, April 11, 2025 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, will present on FibroBiologics’ unique fibroblast cell-based approach for the potential treatment of chronic diseases at The Cell & Gene Meeting On The Mediterranean (Med) in Rome, Italy, from April 15-17, 2025. The Cell & Gene Meeting on the Med is the leading conference bringing together the Advanced Therapy Medicinal Products community from Europe and beyond.
Details of the conference and presentations are as follows:
The Cell & Gene Meeting On The Med
Presentation Title: Restoring Immune system homeostasis using a fibroblast cell-based therapeutic targeting three chronic inflammation-mediated diseases
Presenter: Hamid Khoja, Ph.D., Chief Scientific Officer, FibroBiologics
Location: Salone dei Cavalieri, Section 2
Date and Time: Wednesday, April 16 at 9:00 AM CEST
For more information, please visit FibroBiologics’ website or email FibroBiologics at: info@fibrobiologics.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 240+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
2026 Outlook: automated Agentic AI workflows will rapidly emerge as business imperatives to meet patient…
2026 Outlook: automated Agentic AI workflows will rapidly emerge as business imperatives to meet patient…
OVERLAND PARK, Kan.--(BUSINESS WIRE)--#CMSAlignedNetwork--Netsmart, an industry-leading provider of healthcare technology solutions and services for community-based…
From combination surgeries to advanced skin therapies, The Naderi Center outlines how patients nationwide are…
Potential Schedule III Status Could Improve Legal Clarity for Patients Traveling from Colombia to the…
Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…